CORAL SPRINGS, Florida, May 6, 2015 /PRNewswire/ --

Global pharmaceutical market moves beyond traditional prescription-only medicines as the nutritional sector for weight management, sports nutrition and additional supplements & nutraceuticals accelerate with International growth opportunities. Pharma Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), Nymox Pharmaceutical Corporation (NASDAQ: NYMX), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), NuVasive, Inc. (NASDAQ: NUVA) and Mylan N.V. (NASDAQ: MYL).

Axxess Pharma Inc. (OTC: AXXE) a specialty pharmaceutical and nutritional supplements company, is pleased to announce, research firm Murphy Analytics has re-initiated coverage on AXXE and confirmed a "positive outlook" on the company. The positive outlook is based on Axxess Pharma's projected growth and fundamentals. To view Murphy Analytics May 2015 research report, please click on the link:

Read the full AXXE press release at

Murphy Analytics LLC is owned by Patrick J. Murphy, who has nearly 20 years of capital markets experience, providing institutional investment and transaction analysis across a range of asset classes including microcap equities, commercial real estate debt and equity, municipal derivatives and public finance, venture capital, fixed income, CMBS and mortgage REIT's. In addition to his work with Murphy Analytics, Mr. Murphy also serves as a consultant to a municipal derivatives advisory firm. Mr. Murphy is an alumnus of the University of Notre Dame (1991), with an undergraduate degree in Economics, and earned a Masters Degree in Finance from St. Louis University in 1997.  Mr. Murphy is a CFA Charterholder and a member of the CFA Society of St. Louis.

Mr. Murphy stated, "We are providing a positive outlook on Axxess Pharma, Inc. Muscle Pharma's (OTC: MSLP) growth strategy serves as a guide for AXXE to take share in a market expected to grow up to $160 billion. If AXXE can begin to replicate the MSLP's growth performance in the near term, investors may push the stock past the 52-week high of $0.35."

Earlier this year Axxess Pharma Inc. announced they presented their full TapouT line of products at the nation's largest health and fitness expo, known as the "The Arnold Fitness Expo" which was founded by Arnold Schwarzenegger, former Mr. Universe and 7 time Mr. Olympia. Over 175,000 fitness enthusiasts attended the three day non-stop event and competitions, including the Arnold Strongman Classic, and Arnold Arm Wrestling Classic. During the 3 day event, Axxess Pharma occupied two booths, with one strategically located next to the globally recognized World Wrestling Entertainment (NYSE: WWE) booth. Axxess Pharma also met with buyers from specialty chain stores, where they presented the full line of TapouT products including Ready-To-Drink (RTD's) protein shakes and supplements.

In other pharmaceutical& nutraceutical news and happenings:   Nymox Pharmaceutical Corporation (NASDAQ: NYMX), a biopharmaceutical company, engages in the research and development of products for the aging population. It offers NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products; and AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer’s disease. NYMX closed up over 9% at $1.33 on Tuesday on over 1.2Million shares traded by the market close.  NYMX announced in April long-term clinical trial results from the Company's NX-1207 Phase 2 prostate cancer study NX03-0040. The new results demonstrate statistically significant (p=.0067) better outcomes at up to 2.8 years for NX-1207 treated patients compared to controls. Trial participants included 146 patients with low grade localized prostate cancer at 44 U.S. investigational sites.

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a specialty pharmaceutical company, reported unaudited consolidated financial results for the first quarter of 2015. Total revenues for the first quarter of 2015 increased to $89.5 million, compared with $20.8 million in the first quarter of 2014. This increase was primarily due to the addition of the company's newest product, Makena(R) (hydroxyprogesterone caproate injection), which contributed $55.5 million of product sales to the first quarter results. The company reported net income of $12.9 million, or $0.47 per basic share and $0.39 per diluted share, for the first quarter of 2015, compared with a net loss of $7.1 million, or $0.33 per basic share and diluted share, for the same period in 2014. Non-GAAP net income, or cash earnings1, for the first quarter of 2015 totaled $39.9 million, or $1.17 per diluted share, compared with a non-GAAP net loss of $3.9 million, or $0.33 per diluted share, for the same period in 2014.  Read the full report at

NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced financial results for the quarter ended March 31, 2015. "We are pleased to report strong results for the first quarter 2015, including double-digit revenue growth on a constant currency basis, as well as exceptional operating and EBITDA margin expansion. These outstanding results speak to the ongoing strength of our innovative edge in the marketplace and commitment to leveraging our scale as NuVasive evolves into a global spine player," said Gregory T. Lucier, Chairman and Interim Chief Executive Officer of NuVasive. "Looking ahead, NuVasive's strategy has not changed. We remain laser-focused on increasing our market share in a profitable way, driving innovation in our products and business, and making our culture and people a competitive advantage. Fueled by even greater efficiencies, accelerated globalization and the continued introduction of game- changing innovation, we are well-positioned to continue our positive momentum in 2015 and beyond."  Read the full report at

Mylan N.V. (NASDAQ: MYL) announced its financial results for the quarter ended March 31, 2015.  Mylan CEO Heather Bresch commented, "Our solid first quarter results, which included constant currency revenue growth of 15% and adjusted diluted EPS growth of 6%, are in line with our expectations, marked a great start to 2015 and again demonstrated our commitment to deliver strong operational execution while making progress against our short-term and long-term strategic objectives. During the quarter, Mylan reported positive revenue growth across each of our business segments and regions, with double digit constant currency revenue growth in Europe and Rest of World and high single digit revenue growth in North America and Specialty. We were excited to complete our acquisition of the EPD Business and begin realizing the significant value potential from this transaction. We continue to remain confident in our outlook for the remainder of 2015, and there is no change to our full year financial guidance. We also remain committed to our target of at least $6.001 in adjusted diluted EPS in 2018.  Read the full report at is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at  Follow us on Facebook: and Twitter: 

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has allocated one thousand five hundred dollars for this release regarding the news coverage of the current press release issued by Axxess Pharma Inc. by the company.FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. 

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company: FN Media Group, LLC
Contact email:
U.S. Phone: +1(954)345-0611


SOURCE FN Media Group, LLC